These results in combination with the high expression of HDAC2 in many solid tumors [28] and the recent observation of HDAC2-dependent sensitization of breast and pancreatic cancer cells towards topoisomerase II inhibitors [13,29], of breast cancer cells towards antihormonal therapy [30] and of colon cancer cells towards TNFα [31], characterizes HDAC2 as an important therapeutic target. This evidence concerns the gene HDAC2 and familial pancreatic carcinoma.